Malaria Treatment Market Size & Share | Statistics Report 2028

The malaria treatment market is expected to reach US$ 2,291.49 million by 2028; it is expected to grow at a compound annual growth rate of 4.9% from 2022 to 2028.

Malaria is a life-threatening infectious disease caused by the Plasmodium parasite. The malaria treatment market is growing due to the high prevalence of malaria in low-income countries and global malaria elimination programs initiated by international and national organizations. Also, the increasing launch of advanced diagnostic tools and rising research activities to provide effective therapeutics are further driving the growth of the malaria treatment market.

Market Insights

Government and Private Sector Initiatives to Raise Awareness About Malaria Drive Market Growth

Malaria awareness campaigns help enhance knowledge regarding the disease , improve behaviors promoting health, and promote intersectoral collaboration and social support. The WHO is responsible for coordinating the Global Malaria Programme (GMP) as part of its global efforts to control and eradicate malaria. The program is led by the "Global Technical Strategy for Malaria 2016–2030," which was adopted by the World Health Assembly in May 2015 and was further restructured in 2021. The WHO observes 25 April as World Malaria Day every year to highlight the collective energy and commitment of the malaria communities across the world in uniting for the common objective of freeing the world from malaria.

In 2016, India introduced its first National Framework for Malaria Elimination, which will be valid from 2016 through 2030. In 2019, the Indian government raised funding by more than 25% for the National Vector Borne Disease Control Programme, launched in 2003. The country has also increased its contribution as a donor to the Global Fund to Fight Malaria. Further, in the US, efforts for controlling malaria are made primarily through the President's Malaria Initiative (PMI), overseen by the US Global Malaria Coordinator. According to the Global Health Policy, the US planned the funding of ~US$ 1 billion in FY 2022 for malaria control and research activities. The goal of the US government under the PMI Strategy 2021–2026 is to manage malaria and reduce deaths caused by it, along with a long-term aim of eradicating the disease.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Malaria Treatment Market: Strategic Insights

Market Size Value in	US$ 1,638.27 Million in 2021
Market Size Value by	US$ 2,291.49 Million by 2028
Growth rate	CAGR of 4.9% from 2022 to 2028
Forecast Period	2022-2028
Base Year	2021

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Several governments of various countries across the globe are taking initiatives to create awareness and conduct research for the development of new antimalarial drugs and vaccines. As per the WHO data, total funding for the control and elimination of malaria reached ~US$ 3 billion in 2019; governments of endemic countries, collectively, contributed 31% (~US$ 900 million) of the total fund to create awareness and development of new vaccines. Private companies are also engaging in the fight against malaria and investing heavily in R&D activities. For instance, in 2018, Novartis invested more than US$ 100 million to enhance its research and development activities for next-generation treatments by 2023.

Governments in countries with a high prevalence of malaria are deploying various strategies to eradicate the disease by improving access to treatment and helping communities in malaria-endemic countries in delivering better healthcare. A few of these initiatives are mentioned below.

• Myanmar has a national malaria control plan that is approved by the Global Fund, and it expects to eliminate the disease caused by P. falciparum by 2030. The universal healthcare coverage in the country includes access to malaria diagnosis by microscopy or rapid diagnostic tests (RDTs) and the availability of artemisinin-based combination therapies (ACTs).
• Thailand has implemented the National Strategic Plan for Malaria Elimination that applies an integrated elimination strategy for the elimination of the disease by 2024.
• In January 2020, the Corporate Alliance on Malaria in Africa (CAMA) launched a strategic plan for 2021–2023. This plan aims to reach millions of people with malaria control interventions and scale up prevention activities in the region.
• Abbott collaborated with “Malaria No More” (a nonprofit organization to eradicate malaria) and the Government of Odisha, India, to provide technology, expertise, and funding to facilitate advanced efforts to end malaria in the state. In January 2019, Abbott announced its plans to supply one million RDTs to strengthen Odisha's malaria diagnosis and surveillance system. The company also announced its plans to support “Malaria No More” with the financial aid of US$ 750,000 to support the malaria elimination strategy in the state.

Such initiatives by government and private companies to spread awareness about malaria and reinforce malaria eradication efforts are bolstering the malaria treatment market growth.

Treatment-Based Insights

The malaria treatment market is segmented based on treatment into prescription medications, vaccines, diagnostic tests, and others. The prescription medications are further segmented into chloroquine phosphate, artemisinin-based combination therapies (acts), atovaquone-proguanil, quinine sulfate (qualaquin) with doxycycline, primaquine phosphate, and others. The diagnostic tests segment held the largest market share of US$ 685.69 million in 2021.

Malaria Treatment Market, by Type – 2021 and 2028

Drug Type-Based Insights

The malaria treatment market is bifurcated based on drug type into branded and generic. The generic segment accounted for a larger share of the malaria treatment market in 2021; however, the branded segment is expected to register a higher CAGR of 5.5% during the forecast period.

Route of Administration-Based Insights

Based on route of administration, the malaria treatment market is bifurcated into oral and parenteral & intravenous. The oral segment accounted for the largest share of the market in 2021; however, the parenteral & intravenous segment is expected to register the highest CAGR of 5.4% during the forecast period.

Distribution Channel-Based Insights

Based on distribution channels, the malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment accounted for the largest share of the malaria treatment market in 2021; however, the online pharmacies segment is expected to register the highest CAGR of 6.9% during the forecast period.

End User-Based Insights

Based on drug type, the malaria treatment market is categorized into hospitals, specialty clinics, home care, and others. The hospital’s segment accounted for the largest share of the market in 2021; however, the specialty clinics segment is expected to register the highest CAGR of 5.5% during the forecast period.

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the DVT preventive pump market. The recent key market developments are listed below:

• In January 2022, with the power of partnerships and regular collaborations with The Bill & Melinda Gates Foundation, World Vision, and the President’s Malaria Initiative. Malaria Partners International (MPI) was a key partner in the launch of Rotary’s first Programs of Scale grant, Partners for a Malaria-Free Zambia. With other partners, especially Rotary Clubs in Africa, MPI has supported various projects ranging from small community-based projects to larger global grants. MPI’s Small Grants Program empowers Rotary Clubs in malaria-endemic regions to take direct action to control malaria in their communities. Each project addresses needs carefully defined by community leaders, uses current best practices, and provides measurable goals.
• In December 2021, Cadila Healthcare (Zydus Cadila), a drug-making company, announced its plan for the ongoing development of antimalarial drug ZY19489 (MMV253), with Medicines for Malaria Venture (MMV), which received orphan drug designation from the USFDA. 

Company Profiles

• Zydus Healthcare Ltd         
• Sun Pharmaceutical Industries Ltd           
• Sanofi SA     
• GSK Plc       
• Novartis AG            
• Cipla Ltd      
• Viatris Inc    
• Lupin Ltd     
• AdvaCare Pharma USA LLC           
• VLP Therapeutics LLC